These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 31944367

  • 1. Clinical outcome comparison of Grade Group 1 and Grade Group 2 prostate cancer with and without cribriform architecture at the time of radical prostatectomy.
    Hollemans E, Verhoef EI, Bangma CH, Rietbergen J, Roobol MJ, Helleman J, van Leenders GJLH.
    Histopathology; 2020 Apr; 76(5):755-762. PubMed ID: 31944367
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis.
    Hollemans E, Verhoef EI, Bangma CH, Rietbergen J, Helleman J, Roobol MJ, van Leenders GJLH.
    Mod Pathol; 2019 Jan; 32(1):139-146. PubMed ID: 30349027
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prostate Carcinoma Grade and Length But Not Cribriform Architecture at Positive Surgical Margins Are Predictive for Biochemical Recurrence After Radical Prostatectomy.
    Hollemans E, Verhoef EI, Bangma CH, Rietbergen J, Helleman J, Roobol MJ, van Leenders GJLH.
    Am J Surg Pathol; 2020 Feb; 44(2):191-197. PubMed ID: 31592799
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort.
    Waisman Malaret AJ, Chang P, Zhu K, Zheng Y, Newcomb LF, Liu M, McKenney JK, Brooks JD, Carroll P, Dash A, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Nelson PS, Lin DW, Wagner AA.
    J Urol; 2022 Apr; 207(4):805-813. PubMed ID: 34854745
    [Abstract] [Full Text] [Related]

  • 10. Concordance of cribriform architecture in matched prostate cancer biopsy and radical prostatectomy specimens.
    Hollemans E, Verhoef EI, Bangma CH, Schoots I, Rietbergen J, Helleman J, Roobol MJ, van Leenders GJLH.
    Histopathology; 2019 Sep; 75(3):338-345. PubMed ID: 31045262
    [Abstract] [Full Text] [Related]

  • 11. Comedonecrosis Gleason pattern 5 is associated with worse clinical outcome in operated prostate cancer patients.
    Hansum T, Hollemans E, Verhoef EI, Bangma CH, Rietbergen J, Osanto S, Pelger RCM, van Wezel T, van der Poel H, Bekers E, Helleman J, Remmers S, van Leenders GJLH.
    Mod Pathol; 2021 Nov; 34(11):2064-2070. PubMed ID: 34175896
    [Abstract] [Full Text] [Related]

  • 12. Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups.
    van Leenders GJLH, Kweldam CF, Hollemans E, Kümmerlin IP, Nieboer D, Verhoef EI, Remmers S, Incrocci L, Bangma CH, van der Kwast TH, Roobol MJ.
    Eur Urol; 2020 Feb; 77(2):191-198. PubMed ID: 31439369
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clinicopathological characteristics of glomeruloid architecture in prostate cancer.
    Hollemans E, Verhoef EI, Bangma CH, Rietbergen J, Osanto S, Pelger RCM, van Wezel T, van der Poel H, Bekers E, Helleman J, Roobol MJ, van Leenders GJLH.
    Mod Pathol; 2020 Aug; 33(8):1618-1625. PubMed ID: 32080350
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Alternative prostate cancer grading systems incorporating percent pattern 4/5 (IQ-Gleason) and cribriform architecture (cGrade) improve prediction of outcome after radical prostatectomy.
    Seyrek N, Hollemans E, Andrinopoulou ER, Osanto S, Pelger RCM, van der Poel HG, Bekers E, Remmers S, Schoots IG, van Leenders GJLH.
    Virchows Arch; 2022 Jun; 480(6):1149-1157. PubMed ID: 35157140
    [Abstract] [Full Text] [Related]

  • 19. Percentage Gleason pattern 4 and PI-RADS score predict upgrading in biopsy Grade Group 2 prostate cancer patients without cribriform pattern.
    van der Slot MA, Seyrek N, Kweldam CF, den Bakker MA, Busstra MB, Gan M, Klaver S, Rietbergen JBW, van Leenders GJLH.
    World J Urol; 2022 Nov; 40(11):2723-2729. PubMed ID: 36190529
    [Abstract] [Full Text] [Related]

  • 20. Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stage.
    Nguyen JK, Harik LR, Klein EA, Li J, Corrigan D, Liu S, Chan E, Hawley S, Auman H, Newcomb LF, Carroll PR, Cooperberg MR, Filson CP, Simko JP, Nelson PS, Tretiakova MS, Troyer D, True LD, Vakar-Lopez F, Weight CJ, Lin DW, Brooks JD, McKenney JK.
    Histopathology; 2024 Oct; 85(4):598-613. PubMed ID: 38828674
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.